Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024. In this segment, Dr. Morrison introduces the concept of ...
Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...
Morning Overview on MSN
A myeloma drug that once took an IV drip is now a quick under-the-skin shot
People with multiple myeloma who once spent hours connected to an intravenous drip for daratumumab can now receive the same ...
Oncologists have moved beyond evaluating subcutaneous PD-1 inhibitors as convenient alternatives to intravenous therapy, instead incorporating them into disease-specific treatment strategies as ...
FDA approved pembrolizumab and berahyaluronidase alfa-pmph for patients aged 12 and older with solid tumors. Study MK-3475A-D77 showed a 45% ORR in subcutaneous administration for treatment-naïve ...
hands of a child with juvenile idiopathic arthritis Researchers evaluated the efficacy and safety of abatacept in pediatric patients with polyarticular-course juvenile idiopathic arthritis. ATLANTA — ...
Morning Overview on MSN
Multiple myeloma patients can now get the drug Sarclisa as a quick under-the-skin shot
People living with relapsed or refractory multiple myeloma now have a faster way to receive one of their key treatments. The ...
Bristol Myers Squibb Co (NYSE:BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or ...
CHICAGO — Administering the bispecific antibody amivantamab (Rybrevant) subcutaneously rather than intravenously in combination with lazertinib (Leclaza) not only reduces administration times but also ...
The time required for in-clinic drug administration can substantially affect breast cancer patients' quality of life. Subcutaneous (SC) drug administration, as opposed to intravenous (IV), may reduce ...
Please provide your email address to receive an email when new articles are posted on . The FDA is considering a 500 mg subcutaneous initiation dose. Weekly 500 mg autoinjector and biweekly 10 mg/kg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results